(Q30404393)

21 June 2017

1 reference

title

Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review (English)

1 reference

21 June 2017

1 reference

1 reference

Marc P Girard

1

1 reference

21 June 2017

Saladin Osmanov

series ordinal

2

1 reference

21 June 2017

Olga M Assossou

series ordinal

3

1 reference

21 June 2017

Marie-Paule Kieny

series ordinal

4

1 reference

21 June 2017

language of work or name

English

0 references

publication date

28 June 2011

1 reference

21 June 2017

number of pages

28

1 reference

inferred from page(s)

published in

Vaccine

1 reference

21 June 2017

volume

29

1 reference

21 June 2017

issue

37

1 reference

21 June 2017

page(s)

6191-6218

1 reference

The science of AIDS: a tale of two worlds

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Male circumcision and risk of HIV infection among heterosexual African American men attending Baltimore sexually transmitted disease clinics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Maternal or infant antiretroviral drugs to reduce HIV-1 transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV incidence and sexually transmitted disease prevalence associated with condom use: a population study in Rakai, Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Targeting early infection to prevent HIV-1 mucosal transmission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Pathogenesis of HIV infection: what the virus spares is as important as what it destroys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Persistent immune activation in HIV-1 infection is associated with progression to AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Plasma levels of soluble CD14 independently predict mortality in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Natural regulatory T cells and persistent viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Endocytosis of major histocompatibility complex class I molecules is induced by the HIV–1 Nef protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

7 January 2021

HIV/AIDS vaccines: 2007.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Human immunodeficiency virus-1 vaccine design: where do we go now?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Poxvirus vector-based HIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The role of antibodies in HIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Induction of immunity to human immunodeficiency virus type-1 by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Amplified HIV Transmission during Early‐Stage Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

High rates of forward transmission events after acute/early HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 transmission, by stage of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Acute HIV‐1 Infection: What’s New? Where Are We Going?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Circumcision and risk of HIV infection in Australian homosexual men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

An overview of the relative risks of different sexual behaviours on HIV transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Historical perspective on HIV‐exposed seronegative individuals: has nature done the experiment for us?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Novel alleles of the chemokine-receptor gene CCR5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Human genes that limit AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Genomic approaches to the study of HIV‐1 acquisition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Tracing the regional rise of HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Estimation of HIV incidence in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Risk factors driving the emergence of a generalized heterosexual HIV epidemic in Washington, District of Columbia networks at risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The large intestine as a major reservoir for simian immunodeficiency virus in macaques with long-term, nonprogressing infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 continues to replicate and evolve in patients with natural control of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

CD4 and major histocompatibility complex class I downregulation by the human immunodeficiency virus type 1 nef protein in pediatric AIDS progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Human immunodeficiency virus type 1 Nef associates with lipid rafts to downmodulate cell surface CD4 and class I major histocompatibility complex expression and to increase viral infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Expression of simian immunodeficiency virus nef in immune cells of transgenic mice leads to a severe AIDS-like disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Selective expression of human immunodeficiency virus Nef in specific immune cell populations of transgenic mice is associated with distinct AIDS-like phenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV vaccine design: insights from live attenuated SIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Induction of G2 arrest and binding to cyclophilin A are independent phenotypes of human immunodeficiency virus type 1 Vpr

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

APOBEC-mediated editing of viral RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Cryo-electron microscopy reveals conserved and divergent features of gag packing in immature particles of Rous sarcoma virus and human immunodeficiency virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Distribution and three-dimensional structure of AIDS virus envelope spikes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Molecular architecture of native HIV-1 gp120 trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

TRIM family proteins and their emerging roles in innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Tripartite-motif proteins and innate immune regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Isolation of a new human retrovirus from West African patients with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Identification of a new human immunodeficiency virus type 1 distinct from group M and group O.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A new human immunodeficiency virus derived from gorillas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Evolutionary and immunological implications of contemporary HIV-1 variation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Global trends in molecular epidemiology of HIV-1 during 2000-2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

7 January 2021

Recombination in HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 nomenclature proposal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

AIDS as a zoonosis: scientific and public health implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Chimpanzee reservoirs of pandemic and nonpandemic HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Timing the ancestor of the HIV-1 pandemic strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The evolution of HIV-1 and the origin of AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Widely varying SIV prevalence rates in naturally infected primate species from Cameroon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Hybrid origin of SIV in chimpanzees.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Island biogeography reveals the deep history of SIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The molecular population genetics of HIV-1 group O

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

High GUD incidence in the early 20 century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV escape: there and back again

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV and SIV CTL escape: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Wide variation in the multiplicity of HIV-1 infection among injection drug users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Escape of human immunodeficiency virus from immune control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV evolution: CTL escape mutation and reversion after transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Viral Evolution and Escape during Acute HIV‐1 Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Perils at mucosal front lines for HIV and SIV and their hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The use of nonhuman primate models in HIV vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV swiftly guts the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Microbial Translocation Correlates with the Severity of Both HIV‐1 and HIV‐2 Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Chronic innate immune activation as a cause of HIV-1 immunopathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Mamu-B*08-positive macaques control simian immunodeficiency virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Understanding the benign nature of SIV infection in natural hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Into the wild: simian immunodeficiency virus (SIV) infection in natural hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Nonprogressive and progressive primate immunodeficiency lentivirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Programmed cell death in AIDS-related HIV and SIV infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Th17 cell dynamics in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Th17 cells and HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Th17 cells in pathogenic simian immunodeficiency virus infection of macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Th17 cells in natural SIV hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Th17 and regulatory T cells: implications for AIDS pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Th17 cells, HIV and the gut mucosal barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Lessons learned from the natural hosts of HIV-related viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Th17 cells and regulatory T cells in elite control over HIV and SIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Comprehensive Analysis of Frequency and Phenotype of T Regulatory Cells in HIV Infection: CD39 Expression of FoxP3+T Regulatory Cells Correlates with Progressive Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Lack of clinical AIDS in SIV-infected sooty mangabeys with significant CD4+ T cell loss is associated with double-negative T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

CD4 downregulation by memory CD4+ T cells in vivo renders African green monkeys resistant to progressive SIVagm infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

AIDS vaccine models: challenging challenge viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Core structure of gp41 from the HIV envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The crystal structure of the SIV gp41 ectodomain at 1.47 A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Mechanism of membrane fusion by viral envelope proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV entry and its inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

7 January 2021

Viral membrane fusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The study of elite controllers: a pure academic exercise or a potential pathway to an HIV-1 vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Epigenetic control of IRF1 responses in HIV-exposed seronegative versus HIV-susceptible individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 Nef binds the DOCK2-ELMO1 complex to activate rac and inhibit lymphocyte chemotaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The role of the V3 loop of gp120 in HIV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antibody responses in primary HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The humoral response to HIV-1: new insights, renewed focus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Role of HIV membrane in neutralization by two broadly neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 hides an Achilles' heel in virion lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Cross‐Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV vaccine design and the neutralizing antibody problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antibody vs. HIV in a clash of evolutionary titans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Challenges for structure-based HIV vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

AIDS/HIV. A boost for HIV vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Toward an antibody-based HIV-1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Measuring HIV-1-specific T cell immunity: how valid are current assays?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV‐1 Vaccine Candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Cohorts for the study of HIV‐1-exposed but uninfected individuals: benefits and limitations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Determinants of protection among HIV‐exposed seronegative persons: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Elite control of HIV infection: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Mucosal immunity in HIV controllers: the right place at the right time.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 Epitope-Specific CD8+ T Cell Responses Strongly Associated with Delayed Disease Progression Cross-Recognize Epitope Variants Efficiently

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

First-Class Control of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immunodominant HIV-Specific CD8+T-Cell Responses Are Common to Blood and Gastrointestinal Mucosa, and Gag-Specific Responses Dominate in Rectal Mucosa of HIV Controllers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Understanding animal models of elite control: windows on effective immune responses against immunodeficiency viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vaccine-induced CD8+ T lymphocytes of rhesus monkeys recognize variant forms of an HIV epitope but do not mediate optimal functional activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Prognostic value of HIV-1 Gag-specific CD4+ T-cell responses for progression to AIDS analyzed in a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

CD8+ T cell efficacy in vaccination and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antigen sensitivity and T-cell receptor avidity as critical determinants of HIV control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Fc receptor-mediated antiviral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Fc receptor but not complement binding is important in antibody protection against HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Intracellular Neutralization of HIV Transcytosis across Tight Epithelial Barriers by Anti-HIV Envelope Protein dIgA or IgM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Understanding the "lucky few": the conundrum of HIV-exposed, seronegative individuals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The ‘immunologic advantage’ of HIV-exposed seronegative individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Innate immune activation in primary HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Innate Immunity in Resistance to HIV Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

APOBEC3G levels predict rates of progression to AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

APOBEC3B deletion and risk of HIV-1 acquisition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Evolution of innate and adaptive effector cell functions during acute HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Activation and function of natural killer cell responses during viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

KIR-HLA intercourse in HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Natural resistance to HIV infection: lessons learned from HIV‐exposed uninfected individuals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1-specific T Cell-dependent natural killer (NK) cell activation: major contribution by NK cells to interferon-gamma production in response to HIV-1 antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Impact of a functional KIR2DS4 allele on heterosexual HIV-1 transmission among discordant Zambian couples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Innate immunity in HIV infection and implications for vaccine design: A summary of the workshop held at the National Institute of Allergy and Infectious Diseases, Bethesda on February 25–26, 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The CDK inhibitor p21Cip1/WAF1 is induced by FcgammaR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Genomic Analysis Reveals Pre- and Postchallenge Differences in a Rhesus Macaque AIDS Vaccine Trial: Insights into Mechanisms of Vaccine Efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immunology and the elusive AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The rational design of an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Progress and obstacles in the development of an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

An HIV vaccine--evolving concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Rational antibody-based HIV-1 vaccine design: current approaches and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Virus-like particles as HIV-1 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Molecular and biological characterization of simian-human immunodeficiency virus-like particles produced by recombinant fowlpox viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Why do we not have an HIV vaccine and how can we make one? .

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Public health. AIDS vaccine trial produces disappointment and confusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A review of vaccine research and development: the human immunodeficiency virus (HIV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immunology. Close to the edge: neutralizing the HIV-1 envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Application of the polyvalent approach to HIV-1 vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

7 January 2021

Polyvalent AIDS Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Centralized HIV-1 envelope immunogens and neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV vaccines: mosaic approach to virus diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

GP120: target for neutralizing HIV-1 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Challenges of antibody-mediated protection against HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Structural Characterization of HIV gp41 with the Membrane-proximal External Region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Synthesis and analysis of the membrane proximal external region epitopes of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Trimeric membrane-anchored gp41 inhibits HIV membrane fusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 Tat protein as a potential AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Recent advances in the development of HIV-1 Tat-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The preventive phase I trial with the HIV-1 Tat-based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

T cell immunity in acute HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Induction of Humoral and Cellular Immune Responses to the Human Immunodeficiency Type 1 Virus in Nonhuman Primates by in Vivo DNA Inoculation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Gene inoculation generates immune responses against human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

DNA vaccines against human immunodeficiency virus type 1 in the past decade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Gene transfer to subdermal tissues via a new gene gun design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Electroporation for DNA immunization: clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Nanochemistry-based immunotherapy for HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

DermaVir, a novel HIV immunisation technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The prime-boost strategy: exciting prospects for improved vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Progress toward an HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Viral vectors as potential HIV-1 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Highly attenuated poxvirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Different Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope Specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

AIDS research. Promising AIDS vaccine's failure leaves field reeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Human versus HIV: round 2 defeat in AIDS vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

One step forward, two steps back--will there ever be an AIDS vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

AIDS research. Trials of NIH's AIDS vaccine get a yellow light

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 T-cell vaccines: evaluating the next step

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV/AIDS vaccines: a need for new concepts?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Novel adenovirus vector-based vaccines for HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

New hope for an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Heterologous prime-boost vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Public health. A sound rationale needed for phase III HIV-1 vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immune Responses to HIV Vaccines and Potential Impact on Control of Acute HIV‐1 Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Alphavirus replicon particles as candidate HIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Acute infection with venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV vaccine development by computer assisted design: the GAIA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV preventive vaccine research at the ANRS: the lipopeptide vaccine approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Mucosal HIV vaccines: a holy grail or a dud?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Vaccination strategies to promote mucosal antibody responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV escape from natural killer cytotoxicity: nef inhibits NKp44L expression on CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Specific phenotypic and functional features of natural killer cells from HIV-infected long-term nonprogressors and HIV controllers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A vaccine strategy against AIDS: an HIV gp41 peptide immunization prevents NKp44L expression and CD4+ T cell depletion in SHIV-infected macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

Update on mucosal HIV vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

HIV-1 vaccines and adaptive trial designs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A 2020 vision for vaccines against HIV, tuberculosis and malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

7 January 2021

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

7 January 2021

Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

7 January 2021

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

7 January 2021

Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.085

7 January 2021

10.1016/J.VACCINE.2011.06.085

Identifiers

DOI

1 reference

21 June 2017

1 reference